EDSA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 25.00%

Insider Buying (Last 12 Months): $20,000.00

Insider Selling (Last 12 Months): $0.00

Edesa Biotech Insider Trading History Chart

Edesa Biotech Share Price & Price History

^$4.47

▲ +0.16 (3.71%)

As of 04/25/2024 04:31 PM ET

Days: 30 | 90 | 365

This Apple-like Innovator is Revolutionizing Healthcare

From Wall Street Star | Ad

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Edesa Biotech Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/25/2024	Pardeep Nijhawan	CEO	Buy	5,000	$4.00	$20,000.00	341,702
1/9/2023	Der Velden Peter Van	Major Shareholder	Sell	20,732	$18.62	$386,029.84	23,310
6/30/2022	Pardeep Nijhawan	CEO	Buy	2,857	$11.20	$31,998.40	84,973
6/29/2022	Michael J. Brooks	President	Buy	428	$10.43	$4,464.04	3,748
6/16/2022	Michael J. Brooks	President	Buy	428	$11.27	$4,823.56	3,320
5/27/2022	Pardeep Nijhawan	CEO	Buy	714	$13.44	$9,596.16	82,116
5/25/2022	Michael J. Brooks	President	Buy	500	$12.18	$6,090.00	2,891
5/24/2022	Pardeep Nijhawan	CEO	Buy	285	$12.60	$3,591.00	81,401
3/31/2022	Pardeep Nijhawan	CEO	Buy	285	$20.93	$5,965.05
3/29/2022	Pardeep Nijhawan	CEO	Buy	285	$21.14	$6,024.90
3/17/2022	Pardeep Nijhawan	CEO	Buy	285	$22.82	$6,503.70
3/15/2022	Pardeep Nijhawan	CEO	Buy	285	$19.60	$5,586.00
3/14/2022	Michael J. Brooks	President	Buy	178	$19.53	$3,476.34
3/11/2022	Pardeep Nijhawan	CEO	Buy	1,000	$21.63	$21,630.00
3/10/2022	Michael J. Brooks	President	Buy	142	$22.54	$3,200.68
3/9/2022	Pardeep Nijhawan	CEO	Buy	214	$21.35	$4,568.90
3/8/2022	Michael J. Brooks	President	Buy	178	$20.30	$3,613.40

This Apple-like Innovator is Revolutionizing Healthcare

From Wall Street Star | Ad

Click here to learn more about the booming eHealth industry

SEC Filings (Institutional Ownership Changes) for Edesa Biotech (NASDAQ:EDSA)

5.50% of Edesa Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Edesa Biotech Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/7/2023	CM Management LLC	417,602	$0.26M	0.3%	+11.4%	13.874%
8/4/2023	CM Management LLC	375,000	$0.30M	0.3%	+15.4%	1.821%
5/8/2023	CM Management LLC	325,000	$0.30M	0.4%	+3.9%	1.620%
2/14/2023	Susquehanna International Group LLP	15,211	$33K	0.0%	N/A	0.079%
2/9/2023	CM Management LLC	312,773	$0.68M	0.8%	+25.1%	1.616%
2/7/2023	Lynwood Capital Management Inc.	121,845	$0.26M	0.3%	N/A	0.630%
11/4/2022	CM Management LLC	250,000	$0.23M	0.3%	N/A	1.617%
8/8/2022	Merit Financial Group LLC	20,409	$33K	0.0%	N/A	0.132%
5/5/2022	National Bank of Canada FI	10,000	$30K	0.0%	+1,518.1%	0.072%
11/16/2021	Verition Fund Management LLC	13,502	$100K	0.0%	N/A	0.102%
10/28/2021	180 Wealth Advisors LLC	20,000	$0.16M	0.0%	+33.3%	0.151%
9/17/2021	Virtu Financial LLC	18,938	$100K	0.0%	+17.4%	0.143%
8/13/2021	180 Wealth Advisors LLC	15,000	$70K	0.0%	N/A	0.113%
8/13/2021	Geode Capital Management LLC	74,032	$0.39M	0.0%	+153.3%	0.558%
8/13/2021	Vanguard Group Inc.	109,158	$0.58M	0.0%	+88.9%	0.823%
5/19/2021	Virtu Financial LLC	16,138	$87K	0.0%	N/A	0.122%
5/12/2021	Northern Trust Corp	15,349	$83K	0.0%	N/A	0.116%
5/12/2021	Geode Capital Management LLC	29,229	$0.16M	0.0%	N/A	0.222%
2/10/2021	Renaissance Technologies LLC	74,100	$0.32M	0.0%	N/A	0.704%
1/19/2021	FNY Investment Advisers LLC	75,000	$0.32M	0.1%	-37.7%	0.713%
10/9/2020	FNY Investment Advisers LLC	120,407	$0.97M	0.4%	N/A	1.279%

Data available starting January 2016

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Today's Range

Now: $4.47

$4.46

$4.60

50 Day Range

MA: $4.56

$4.06

$5.65

52 Week Range

Now: $4.47

$2.46

$8.61

Volume

2,336 shs

Average Volume

12,194 shs

Market Capitalization

$14.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Edesa Biotech?: Edesa Biotech's top insider shareholders include:
Pardeep Nijhawan (CEO)
Der Velden Peter Van (Major Shareholder)
Michael J Brooks (President)
Learn More about top insider investors at Edesa Biotech.